The importance of data transparency in healthcare: Variances in patient and claims counts
At Symphony Health, an ICON plc company, we recognise that data transparency is paramount for fostering trust and confidence in the decisions data informs. In an industry where data-driven decisions underpin patient care, business strategies, and policymaking, the true power of data lies not only in its quantity or availability, but in a deep understanding of its origin, definitions, and the interpretations it supports.
Healthcare professionals and clients frequently seek clarity when they observe changes in patient or claim counts after data updates or restatements. This blog explains why these variances occur and how Symphony Health’s commitment to data transparency ensures clients can confidently interpret and utilise their refreshed datasets.
Why do patient and claim counts change?
Restatements in data deliverables can lead to significant and sometimes unexpected changes in patient and claim counts. These adjustments typically arise due to one of three factors:
- Data events: any disruption to the inflow of data that affected and continues to reshape the volume and flow of healthcare data
- Inclusion of new data sources: a quality data supplier should constantly be looking for and investing in new data sources, such as specialty pharmacy, medical office, and hospital claims data
- Changes in privacy requirements: Protecting privacy should be a critical component of a quality supplier. Expert guidance regarding how data can be reported in a compliant manner evolves over time.
Each of these factors influences the data in unique ways that can impact how clients interpret and utilise their deliverables.
Data Events
Data events, for example, can create variances when there are differences in the time periods used for qualifying patients within a dataset.
Patients are included based on defined qualifying events that fall within specific timeframes, such as those related to diagnoses (Dx), prescriptions (Rx), procedures (Px), or surgical interventions (Sx). If the timeframe of a refreshed patient dataset does not match the legacy dataset, the pool of qualifying patients can shift, leading to fluctuations in reported counts. These time-sensitive criteria ensure that only relevant patient data is considered, but they can also mean that previously qualifying patients might be excluded, or new ones included when the dataset’s reference period is updated.
Additionally, modifications to qualifying markets can significantly impact which patients are included. Any changes made to the list of qualifying Rx, Dx, or Px codes can directly influence patient counts. For instance, adding qualifying products, diagnoses, or procedures may result in increased patient counts, while removing such qualifiers will generally lead to reduced counts. For example, if you were receiving a patient dataset containing all solid tumors and decided to narrow the focus to only include breast cancer, then once the data is refreshed, any patients lacking claims indicating breast cancer would no longer be present. This example highlights how modifications to qualifying market criteria can substantially alter patient inclusion and must be carefully considered when analysing restated data deliverables.
Patient age and birth year is another critical factor that can impact patient counts. Patients over the age of 100 at the time of refresh are excluded to meet age limitations, while those aged between 80 and 100 are uniformly reported as age 80. Additionally, patients with invalid birth year data or birth years set in the future are excluded, along with all associated claims. These age-based criteria help maintain data accuracy and compliance but can lead to reduced counts if patients fall outside these thresholds.
Understanding these intricacies is essential for interpreting changes correctly and maintaining trust in the data’s reliability and applicability.
Inclusion of New Data Sources
The addition of new data sources during a data refresh can lead to the inclusion of new patients and potential new physicians, as well as additional claims for both existing and new patients. This process may also bring new plans into the dataset. While these updates enhance the overall depth and comprehensiveness of the data, they can result in noticeable variations when clients compare refreshed deliverables to their legacy counterparts. Understanding these changes is key to appreciating the expanded scope and richer insights provided by updated datasets.
Changes in privacy requirements
To comply with privacy standards such as HIPAA, data suppliers should enforce data remediations that modify or remove sensitive personal information, including birth, death, and residence data, as well as military status, marital status, and employer group plans. These measures are implemented with precision to maintain patient privacy while ensuring the data's continued utility. Key impacts on fact tables include nullification of restricted diagnosis codes and adjustments to Rx numbers within prescription records. Diagnosis records with restricted codes are removed, affecting patient qualification, and similar rules apply to Px and Sx records, resulting in fewer rows where such codes are present.
Dimension tables are also affected, with restricted diagnosis, procedure, and surgical codes being removed, leading to a reduction in the number of rows. Practitioner records are updated to retain only compliant location data, ensuring adherence to privacy regulations. Additionally, sensitive details in the plan and payment sub type dimensions are removed, potentially resulting in fewer matching records. These adjustments are crucial for protecting sensitive information while providing clients with transparent, compliant datasets.
In conclusion, understanding the underlying reasons for dataset changes can be complex, but transparency is essential. Symphony Health is dedicated to ensuring that clients can trust and interpret their data confidently. By providing clarity on data events, source additions, and privacy remediations, we empower clients to discern whether observed changes are typical or not. Transparency is essential when navigating data changes. Choose a provider who shares this value: Symphony Health.
In this section
-
Digital Disruption
-
Clinical strategies to optimise SaMD for treating mental health
-
Digital Disruption: Surveying the industry's evolving landscape
- AI and clinical trials
-
Clinical trial data anonymisation and data sharing
-
Clinical Trial Tokenisation
-
Closing the evidence gap: The value of digital health technologies in supporting drug reimbursement decisions
-
Digital disruption in biopharma
-
Disruptive Innovation
- Remote Patient Monitoring
-
Personalising Digital Health
- Real World Data
-
The triad of trust: Navigating real-world healthcare data integration
-
Clinical strategies to optimise SaMD for treating mental health
-
Patient Centricity
-
Agile Clinical Monitoring
-
Capturing the voice of the patient in clinical trials
-
Charting the Managed Access Program Landscape
-
Developing Nurse-Centric Medical Communications
- Diversity and inclusion in clinical trials
-
Exploring the patient perspective from different angles
-
Patient safety and pharmacovigilance
-
A guide to safety data migrations
-
Taking safety reporting to the next level with automation
-
Outsourced Pharmacovigilance Affiliate Solution
-
The evolution of the Pharmacovigilance System Master File: Benefits, challenges, and opportunities
-
Sponsor and CRO pharmacovigilance and safety alliances
-
Understanding the Periodic Benefit-Risk Evaluation Report
-
A guide to safety data migrations
-
Patient voice survey
-
Patient Voice Survey - Decentralised and Hybrid Trials
-
Reimagining Patient-Centricity with the Internet of Medical Things (IoMT)
-
Using longitudinal qualitative research to capture the patient voice
-
Agile Clinical Monitoring
-
Regulatory Intelligence
-
An innovative approach to rare disease clinical development
- EU Clinical Trials Regulation
-
Using innovative tools and lean writing processes to accelerate regulatory document writing
-
Current overview of data sharing within clinical trial transparency
-
Global Agency Meetings: A collaborative approach to drug development
-
Keeping the end in mind: key considerations for creating plain language summaries
-
Navigating orphan drug development from early phase to marketing authorisation
-
Procedural and regulatory know-how for China biotechs in the EU
-
RACE for Children Act
-
Early engagement and regulatory considerations for biotech
-
Regulatory Intelligence Newsletter
-
Requirements & strategy considerations within clinical trial transparency
-
Spotlight on regulatory reforms in China
-
Demystifying EU CTR, MDR and IVDR
-
Transfer of marketing authorisation
-
An innovative approach to rare disease clinical development
-
Therapeutics insights
- Endocrine and Metabolic Disorders
- Cardiovascular
- Cell and Gene Therapies
- Central Nervous System
-
Glycomics
- Infectious Diseases
- NASH
- Oncology
- Paediatrics
-
Respiratory
-
Rare and orphan diseases
-
Advanced therapies for rare diseases
-
Cross-border enrollment of rare disease patients
-
Crossing the finish line: Why effective participation support strategy is critical to trial efficiency and success in rare diseases
-
Diversity, equity and inclusion in rare disease clinical trials
-
Identify and mitigate risks to rare disease clinical programmes
-
Leveraging historical data for use in rare disease trials
-
Natural history studies to improve drug development in rare diseases
-
Patient Centricity in Orphan Drug Development
-
The key to remarkable rare disease registries
-
Therapeutic spotlight: Precision medicine considerations in rare diseases
-
Advanced therapies for rare diseases
-
Transforming Trials
-
Accelerating biotech innovation from discovery to commercialisation
-
Ensuring the validity of clinical outcomes assessment (COA) data: The value of rater training
-
Linguistic validation of Clinical Outcomes Assessments
-
Optimising biotech funding
- Adaptive clinical trials
-
Best practices to increase engagement with medical and scientific poster content
-
Decentralised clinical trials
-
Biopharma perspective: the promise of decentralised models and diversity in clinical trials
-
Decentralised and Hybrid clinical trials
-
Practical considerations in transitioning to hybrid or decentralised clinical trials
-
Navigating the regulatory labyrinth of technology in decentralised clinical trials
-
Biopharma perspective: the promise of decentralised models and diversity in clinical trials
-
eCOA implementation
- Blended solutions insights
-
Implications of COVID-19 on statistical design and analyses of clinical studies
-
Improving pharma R&D efficiency
-
Increasing Complexity and Declining ROI in Drug Development
-
Innovation in Clinical Trial Methodologies
- Partnership insights
-
Risk Based Quality Management
-
Transforming the R&D Model to Sustain Growth
-
Accelerating biotech innovation from discovery to commercialisation
-
Value Based Healthcare
-
Strategies for commercialising oncology treatments for young adults
-
US payers and PROs
-
Accelerated early clinical manufacturing
-
Cardiovascular Medical Devices
-
CMS Part D Price Negotiations: Is your drug on the list?
-
COVID-19 navigating global market access
-
Ensuring scientific rigor in external control arms
-
Evidence Synthesis: A solution to sparse evidence, heterogeneous studies, and disconnected networks
-
Global Outcomes Benchmarking
-
Health technology assessment
-
Perspectives from US payers
-
ICER’s impact on payer decision making
-
Making Sense of the Biosimilars Market
-
Medical communications in early phase product development
-
Navigating the Challenges and Opportunities of Value Based Healthcare
-
Payer Reliance on ICER and Perceptions on Value Based Pricing
-
Payers Perspectives on Digital Therapeutics
-
Precision Medicine
-
RWE Generation Cross Sectional Studies and Medical Chart Review
-
Survey results: How to engage healthcare decision-makers
-
The affordability hurdle for gene therapies
-
The Role of ICER as an HTA Organisation
-
Strategies for commercialising oncology treatments for young adults
-
Blog
-
Videos
-
Webinar Channel